City of Hope Developing Blood Test for Early Colorectal Cancer Detection
The screening tool aims to identify the disease in adults under 50, a population experiencing a significant increase in cases.
The screening tool aims to identify the disease in adults under 50, a population experiencing a significant increase in cases.
Early results indicate the process could reduce sample preparation time by approximately 40% to 50%, while improving consistency by removing variability linked to staining conditions.
In studies using National Lung Screening Trial biospecimens, a liquid biopsy assay showed similar sensitivity to low-dose CT screening and detected cancers missed by imaging.
New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.
Read MoreMonitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Read MoreThe study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.”
Read MoreResearch shows optical genome mapping identifies genomic changes in nearly 98% of T-cell acute lymphoblastic leukemia cases compared to 55% with traditional analysis.
Read MoreThe digital pathology platform provides patient-specific risk estimates to help clinicians tailor treatment for metastatic hormone-sensitive disease.
Read MoreResults from the NHS-Galleri study show a 26% reduction in metastatic cancer diagnoses by the third round of screening.
Read MoreThe diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.
Read MoreThe test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
Read MoreClinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read MoreThe tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read MoreResults from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MoreThe authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read MoreThe multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read MoreThe study identifies HAVCR1 as a tool for earlier detection and treatment monitoring for primary central nervous system lymphoma.
Read MoreThe panel integrates biomarker testing and digital tools to support fibrosis risk assessment and liver cancer surveillance.
Read More